Brielle Benyon

Articles

Targeted Treatment Provides ORR and PFS Benefit in Pretreated Metastatic Solid Tumors

October 1st 2024

Targeted treatment as determined by mutational status was associated with ORR and PFS benefits in pretreated patients with metastatic solid tumors.

Talquetamab Produces Responses in R/R Myeloma After Prior T-Cell–Directed Therapies

June 12th 2024

Talquetamab proved safe and effective for relapsed/refractory myeloma, even in patients with comorbidities.

Linvoseltamab Generates Efficacy Similar to That Seen With Teclistamab in R/R Myeloma

June 7th 2024

Linvoseltamab elicited outcomes equivalent to those seen with teclistamab in patients with triple-class exposed relapsed/refractory multiple myeloma.

Amivantamab Plus Lazertinib Improves PFS Irrespective of Risk in EGFR-Mutant NSCLC

June 1st 2024

Amivantamab plus lazertinib improved progression-free survival vs osimertinib as frontline therapy in patients with high-risk, EGFR-mutant advanced NSCLC.

BrECADD Regimen Improves PFS vs eBEACOPP Regimen in Advanced Classical Hodgkin Lymphoma

June 1st 2024

Four-year progression-free survival outcomes revealed the BrECADD regimen was superior to the eBEACOPP regimen, and BrECADD had a promising benefit-risk profile.

Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give Birth

May 23rd 2024

Most women who attempted to conceive following treatment for stage I to III breast cancer were able to become pregnant at least once.

Underutilization of HRR Mutation Testing in Clinic Signals Unmet Need in mCRPC

January 25th 2024

Sub-optimal integration of HRR mutation testing into clinical practice leads to a negative impact on treatment selection and outcomes in mCRPC.

Real-World Data Identify Factors Associated With Long-Term Response to Regorafenib in mCRC

January 20th 2024

Favorable ECOG PS, lower LDH levels, and absence of BRAF and KRAS mutations at baseline were associated with long-term response to regorafenib in patients with mCRC in the real world.

Revolutionizing GI Oncology Around the Globe

December 28th 2023

Eileen M. O’Reilly, MD, traveled a serendipitous journey from Ireland to the United States, where she has made her mark on transforming gastrointestinal cancer treatment.

NX-2127 Elicits Responses With Manageable Safety in Heavily Pretreated B-cell Malignancies

December 12th 2023

NX-2127 showcased early efficacy in the form of responses with an acceptable toxicity profile in patients with relapsed or refractory B-cell malignancies, according to data from the ongoing phase 1 NX-2127-001 trial.

Adjuvant T-DM1 Provides Sustained Survival Benefit in HER2+ Early Breast Cancer

December 8th 2023

Adjuvant ado-trastuzumab emtansine continued to improve overall survival and invasive disease-free survival vs trastuzumab after 8.4 years of follow-up in patients with HER2-positive early breast cancer and residual invasive disease following neoadjuvant therapy enrolled in the phase 3 KATHERINE trial.

Ribociclib Plus Nonsteroidal Aromatase Inhibitor Improves iDFS in HR+ HER2- Early Breast Cancer

December 8th 2023

A continued statistically significant improvement in iDFS was observed for patients with HR-positive, HER2-negative early-stage breast cancer who received ribociclib plus a nonsteroidal AI vs a nonsteroidal AI alone, according to the final iDFS analysis of the phase 3 NATALEE trial.

Belzutifan Generates Superior PFS, ORR in Pretreated Advanced ccRCC

October 21st 2023

Treatment with belzutifan produced improvements in progression-free survival and objective response rate vs everolimus in patients with pretreated advanced clear cell renal cell carcinoma.

Acalabrutinib Has Tolerable Safety Profile in Older, Frail CLL Population

June 9th 2023

Acalabrutinib is safe in patients with chronic lymphocytic leukemia who are at least 80 years of age and/or frail.

Cabozantinib Plus Nivolumab/Ipilimumab Improves PFS, DCR in Metastatic Soft Tissue Sarcoma

June 5th 2023

The addition of nivolumab and ipilimumab to cabozantinib led to an improvement in disease control rate and progression-free survival vs cabozantinib alone in patients with metastatic soft tissue sarcoma.

Telephone-Based Weight Loss Program Is Effective for Breast Cancer Survivors

May 25th 2023

A telephone and web-based weight loss intervention was successful in helping patients with breast cancer who were overweight or obese lose weight—which can ultimately lead to improved outcomes.

Awareness of the HPV-Cancer Connection, Vaccine Rates Are Lagging

April 18th 2023

Fewer Americans are aware of the fact that the human papillomavirus can cause certain types of cancer, and vaccination rates against the virus are lagging, according to recent research presented at the AACR Annual Meeting 2023.

Lutetium 177 PSMA-617 Following Radium-223 Is Active and Safe in mCRPC

February 16th 2023

Sequencing treatment with Lutetium 177 PSMA-617 after radium-223 was safe and well tolerated and demonstrated similar overall survival in patients with metastatic castration-resistant prostate cancer regardless of whether they received 177Lu-PSMA-617 within 6 months or after 6 months of completing radium-223.

Ibrutinib Improves Time to Next Therapy Vs Acalabrutinib in Real-world Analysis of Patients With CLL

December 12th 2022

The use of frontline ibrutinib was associated with a longer time to next treatment compared with acalabrutinib in patients with chronic lymphocytic leukemia.

Zanubrutinib Delivers Durable Disease Control in Relapsed/Refractory MZL

December 11th 2022

Zanubrutinib sustained high response rates and led to durable disease control with low incidence of hypertension and atrial fibrillation in patients with relapsed/refractory marginal zone lymphoma, according to findings from the final analysis of the phase 2 MAGNOLIA trial.